GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Loans Receivable

Affimed NV (Affimed NV) Loans Receivable : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Affimed NV Loans Receivable?

Affimed NV's Loans Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.


Affimed NV Loans Receivable Historical Data

The historical data trend for Affimed NV's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Loans Receivable Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Affimed NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Affimed NV Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Affimed NV Loans Receivable Related Terms

Thank you for viewing the detailed overview of Affimed NV's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Affimed NV (Affimed NV) Business Description

Traded in Other Exchanges
Address
Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Affimed NV (Affimed NV) Headlines

From GuruFocus

Affimed to Present at the 2023 Jefferies Healthcare Conference

By sperokesalga sperokesalga 05-30-2023

Affimed to Present at the SVB Securities 2023 Global Biopharma Conference

By Stock market mentor Stock market mentor 02-08-2023

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

By Stock market mentor Stock market mentor 01-09-2023